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Adverse Events Associated with 
jl,-agonists 
Tremor and headaches are reported as common 
adverse events to &agonists. However, rapid, 
tachyphylaxis usually occurs. There is some concern 
with the short-acting /3,-agonist, fenoterol, which 
has the least selectivity for &compared with 
/3,-adrenoceptors (1). Bremner et al. (2) compared 
formoterol(24 pug), fenoterol(400 pug) and salbutamol 
(4OOpg) in an acute event study. Fenoterol had 
the greatest, and salbutamol the least, cardiac and 
metabolic effects. 
One question still to be answered is whether 
there is tachyphylaxis to the beneficial effects of 
&agonists. There are a number of studies that 
indicate that regular use of long-acting &agonists 
results in tolerance to bronchoprotective effects. 
However, in the clinic, sahneterol and formoterol 
work very well as bronchodilators following long- 
term administration, and therefore tachyphylaxis 
may be largely irrelevant both in terms of efficacy 
and safety. 
Adverse Events Associated with Inhaled 
Corticosteroids 
Inhaled corticosteroids can have both local and 
systemic adverse events. Local adverse events include 
dysphonia and oral candidiasis. The systemic adverse 
events of most concern in adults are osteoporosis and 
adrenal suppression, but skin thinning/purpura may 
be a concern to patients, as well as weight gain, 
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cataracts, diabetes mellitus, infection and emotional 
lability. 
Osteoporosis 
Studies of a cross-sectional design are limited by the 
long-term consequences of previous systemic steroid 
therapy. Longitudinal study design is therefore pre- 
ferred, using prospective rather than retrospective 
data, with a sufficient number of patients and 
duration to give the study the necessary power for 
interpretation. 
Hanania et al. (3) reported a study of 18 patients 
receiving moderately high dose 800-2000 &day 
beclomethasone dipropionate (BDP) or budesonide 
(median 1323 ,&day), and 18 with only broncho- 
dilator therapy. Patients were followed over 
24 months. Of all the biochemical markers studied, 
only osteocalcin showed a difference between the two 
groups. Bone densitometry (reduced z-score) was 
observed in the femur neck in patients receiving 
inhaled corticosteroids, with no difference in the 
lumbar spine. 
Herrala et al. (4) studied 38 treatment-naive female 
patients, with a mean age 53 years; 13 in each group 
were postmenopausal. Treatment was with inhaled 
corticosteroids, at a moderate dose (1000 pg/day) 
using a volumatic spacer to overcome any problems 
of gastrointestinal absorption, for 12 months. No 
differences in bone densitometry were observed at 0, 
6, and 12 months. 
Boulet et al. (5) compared bone densitometry of 
patients receiving moderately high doses of either 
BDP or budesonide (mean dose 1140 ,&day), for an 
average of 34 months, with that of patients with mild 
asthma, receiving low doses (mean dose 89pg/day), 
for an average of 15.7 months. No differences in bone 
densitometry measurements were reported between 
the two groups. This would suggest that bone 
densitometry may not be affected by short-term, 
moderately high doses of inhaled corticosteroids, 
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in patients without any previous systemic steroid 
treatment. 
Skin thinninglpurpura 
There are very few data available on the effects 
of inhaled corticosteroids on skin thinning. Capewell 
et al. (6), using a cross-sectional study, examined the 
effects of prednisolone, low-dose inhaled corticoster- 
oids and high-dose inhaled corticosteroids, compared 
with control patients, on skin thickness in three 
regions. The results showed a graded difference in the 
degree of skin thinning, being normal in controls, 
with the amount of thinning and purpura increasing 
from low-dose to high-dose inhaled corticosteroids, 
and being highest with systemic steroids. 
In a study examining procollagen peptide I & III 
levels in suction blister fluid, Autio et al. (7) reported 
that following 6 weeks of inhaled corticosteroids 
(either budesonide 400 or 1600 ,ug/day) there was a 
39-63% reduction compared with nedocramil(l6 mg). 
No difference in peptide levels were observed between 
the two doses of inhaled corticosteroids. 
Diabetes mellitus 
Over the past 10 years, only two studies have reported 
onset of diabetes mellitus during clinical studies using 
inhaled corticosteroids (both were comparisons of 
fluticasone propionate, 1000 pglday with budesonide, 
2000pglday) (8,9). In the first study, only 1 patient 
(n=213) and in the second study, 2 patients (n=154) 
developed diabetes mellitus; it is likely therefore that 
the condition developed by chance. 
One study (lo), examined high-dose BDP (2000 ,ug/ 
day) for a 2-week period in 14 control patients and 10 
elderly patients with non-insulin-dependent diabetes 
mellitus that was controlled by diet alone. Glucose 
tolerance tests, and levels of insulin, cholesterol and 
triglycerides all showed no difference between the two 
groups. 
Infections and Cataracts 
Local infections, usually oral candidiasis, are rela- 
tively common in patients using inhaled cortico- 
steroids, but there are no reports of systemic 
infections, There is anecdotal evidence of an 
increased incidence of cataracts in patients receiving 
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inhaled corticosteroids, but this is confounded by 
previous exposure to systemic steroids. However, a 
recent report studying intra-ocular pressure and 
glaucoma in a large number of elderly patients 
showed an increased risk of ocular hypertension with 
the use of high doses of inhaled corticosteroids for 
more than 3 months (11). 
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